EUCTR2011-003812-22-ES进行中（未招募）不适用
A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With Acute BacterialSkin and Skin Structure Infections
Cerexa, Inc. (subsidary of Forest Laboratories)0 个研究点目标入组 270 人开始时间: 2012年7月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 270
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Informed consent in writing from parent(s) or legally acceptable representative(s) and informed assent from subject (if age appropriate according to local requirements)
- •2. Male or female, 2 months to < 18 years old
- •3. Presence of ABSSSI warranting 3 days of initial hospitalization and a minimum of 3 days of IV antibacterial therapy, but no more than 14 days of total therapy (IV and PO combined)
- •4. Presence of ABSSSI with measurable margins of erythema (cellulitis), that includes deeper and/or extensive soft tissue involvement* (eg, deep and extensive cellulitis, erysipelas, or major abscess), or requires significant therapeutic surgical intervention** (eg, major abscess or an infected wound
- •[postoperative surgical or traumatic]), defined as:
- •? Abscess: presence of a loculated fluid collection with erythema (ie, cellulitis) extending from the abscess margin and onset within 7 days before randomization. A ?major abscess? either extends to deeper soft tissue or requires significant surgical intervention. Incision and drainage should be conducted within 24 hours after first dose of IV study drug. A minimum area of surrounding erythema (cellulitis) around the abscess is required for a subject to be enrolled in the study; refer to Appendix I for calculation and minimum size requirement.
- •? Wound infection: presence of either purulent/seropurulent discharge from the surgical/traumatic wound with erythema (ie, cellulitis) surrounding the wound margin. Onset must have occurred within 7 days before randomization and within 30 days following the trauma or surgical procedure. A minimum size of wound infection is required for a subject to be enrolled in the
- •? Cellulitis/erysipelas: presence of advancing erythema, induration/edema, and heat with onset within 7 days before randomization. A minimum size of cellulitis/erysipelas is required for a subject to be enrolled in the study;
- •* Deeper soft tissue: subdermal tissue, including subcutaneous fat
- •** Significant surgical intervention: a major invasive therapeutic procedure (not including commonly performed minor procedures such as suture removal, superficial debridement of devitalized tissue, or routine wound care)
- •5. In addition to erythema (cellulitis), presence of at least 1 of the following local signs and symptoms of acute infection (present for < 10 days):
- •? Purulent or seropurulent drainage or discharge
- •? Induration/edema
- •? Fluctuance
- •? Heat or localized warmth
- •AND the presence of at least 1 of the following systemic signs:
- •? Fever (> 38°C [100.4°F]) or hypothermia (< 35°C [95.0°F]). Temperature should not be measured by the axillary method.
- •? WBC count > 12,000/mm3
- •? > 10% immature neutrophils (bands) regardless of total peripheral WBC
- •6. Female subjects who have reached menarche must have a negative urine pregnancy test
- •7. Female subjects who have reached menarche and are sexually active must be willing to practice sexual abstinence or dual methods of birth control (eg, condom or diaphragm with spermicidal foam or gel)
- •during treatment and for at least 28 days after the last dose of any study drug (IV or PO)
- •8. Sufficient IV access to receive medication
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 270
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Documented history of any hypersensitivity or allergic reaction to vancomycin, aztreonam, or any ?-lactam antimicrobial
- •2. Uncomplicated skin and soft tissue infections such as simple abscess, impetiginous lesions, superficial or small size cellulitis, furunculosis, carbunculosis, or folliculitis.
- •3. Skin and skin structure infections with a high cure rate after surgical incision alone or after aggressive local skin care.
- •4. Skin and soft tissue infections with any of the following characteristics:
- •? Known or suspected anaerobic pathogens, Pseudomonas, Proteus, or ESBL-producing organisms
- •? Known or suspected fungal, parasitic, or viral pathogens as the cause for the ABSSSI
- •? Decubitus ulcer or diabetic foot infection
- •? Complicated by osteomyelitis, septic arthritis, or endocarditis
- •? Burn wound
- •? Underlying inflammatory skin disease that may obscure determination of response, such as atopic dermatitis
- •? Human or animal bite
- •? Rapidly necrotizing process such as necrotizing fasciitis
- •? Presence of prosthetic materials
- •? Need for amputation
- •5. More than 24 hours of any systemic antibacterial therapy within 96 hours before randomization.
- •EXCEPTIONS:
- •a. Microbiological or clinical treatment failure with a nonstudy
- •antibacterial therapy that was administered for at least 72 hours.
- •Failure must be confirmed by either a microbiological laboratory
- •report or documented worsening clinical signs or symptoms.
- •b. Low-dose tetracycline derivative for acne (eg, doxycycline 50 mg
- •6. Requirement for any potentially effective concomitant systemic antibacterial therapy.
- •7. History of seizures, excluding well-documented febrile seizure of childhood.
- •8. Creatinine clearance < 50 mL/min/1.73 m2 as calculated using the updated Schwartz ?bedside? formula (Schwartz et al, 2009):
- •0.413 × Height (length) (cm) CrCl (mL/min/1.73 m2) =
- •Serum creatinine (mg/dL)
- •9. Clinical signs or suspicion of meningitis
- •10. Current septic shock or acute hemodynamic instability including a requirement for pressor support.
- •11. Evidence of significant hepatic, hematologic, or immunocompromising condition (any of the following):
- •? Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the upper limit of normal (× ULN) or total bilirubin level > 2 × ULN
- •? Known acute viral hepatitis
- •? Neutropenia (< 500 neutrophils/mm3)
- •? Thrombocytopenia (< 60,000 platelets/mm3)
- •? If HIV positive, has CD4 count < 250 cells/mm3 at the last measurement or history of AIDS-defining illness
- •? Bone marrow ablative therapy, including bone marrow transplantation, within the last 12 months
- •? Bone marrow or solid organ recipients who have had an episode of graft versus host disease or acute rejection episode, respectively, within the last 6 months
- •? Severe combined immunodeficiency disorder (SCID)
- •? Requirement for high-dose (eg, > 20 mg/day of prednisone or equivalent) or prolonged systemic corticosteroid therapy. Short courses of corticosteroids, such as those for currently worsening asthma, are permitted.
- •12. Evidence of immediately life-threatening disease, progressively fatal disease, or life expectancy of ? 3 months
- •13. Females who are currently pregnant or breastfeeding
- •14. Participation in any study involving administration of an investigational agent or device within 30 days before the start of first dose of IV study drug or previously participated in the current study or in another study of ceftaroline fosamil (in which
- •an active agent was received)
研究者
相似试验
进行中（未招募）
不适用
A Blind (treatment to be received is not known to the observer), Controlled (a chance to receive any of the treatments to be given) Study to Assess How Safe and Acceptable Ceftaroline and Ceftriaxone are and Whether both can be Used to Treat Young Children Who have Pneumonia and Need to be Hospitalized.Community-acquired Bacterial PneumoniaMedDRA version: 14.1Level: PTClassification code 10035664Term: PneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10004051Term: Bacterial pneumonia, unspecifiedSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10060946Term: Pneumonia bacterialSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-002203-18-PLCerexa, Inc.160
进行中（未招募）
不适用
A Blind (treatment to be received is not known), Controlled (a chance to receive any of the treatments to be given) Study to Assess How Safe and Acceptable Ceftaroline and Ceftriaxone are and Whether both can be Used to Treat Young Children Who have Pneumonia and Need to be Hospitalized.Community-acquired Bacterial PneumoniaMedDRA version: 14.1Level: PTClassification code 10035664Term: PneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10004051Term: Bacterial pneumonia, unspecifiedSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: PTClassification code 10060946Term: Pneumonia bacterialSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 14.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-002203-18-HUCerexa, Inc. (subsidary of Forest Laboratories)160
进行中（未招募）
不适用
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects with Complicated Skin InfectionsAcute Bacterial Skin and Skin Structure InfectionsMedDRA version: 16.0Level: PTClassification code 10040872Term: Skin infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-003812-22-LVCerexa, Inc. (subsidary of Forest Laboratories)270
进行中（未招募）
1 期
A Blind (treatment to be received is not known), Controlled (a chance to receive any of the treatments to be given) Study to Assess How Safe and Acceptable Ceftaroline and Ceftriaxone are and Whether both can be Used to Treat Young Children Who have Pneumonia and Need to be Hospitalized.Community-acquired Bacterial PneumoniaMedDRA version: 15.0Level: PTClassification code 10035664Term: PneumoniaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 15.0Level: LLTClassification code 10004051Term: Bacterial pneumonia, unspecifiedSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 15.0Level: PTClassification code 10060946Term: Pneumonia bacterialSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 15.0Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-002203-18-ESCerexa, Inc. (subsidary of Forest Laboratories)161
进行中（未招募）
不适用
A Blind (treatment to be received is not known), Controlled (a chance to receive any of the treatments to be given) Study to Assess How Safe and Acceptable Ceftaroline and Ceftriaxone are and Whether both can be Used to Treat Young Children Who have Pneumonia and Need to be Hospitalized.EUCTR2012-002203-18-GRCerexa, Inc. (subsidary of Forest Laboratories)160